You are here

Article Text

Article menu
Download PDFPDF
PostScript
Letter
Vonoprazan Helicobacter pylori eradication therapy: ethical and interpretation issues

https://doi.org/10.1136/gutjnl-2016-311796

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    Footnotes

    • Funding DYG is supported in part by the Office of Research and Development Medical Research Service Department of Veterans Affairs, Public Health Service grant DK56338 which funds the Texas Medical Center Digestive Diseases Center.

    • Competing interests DYG is a paid consultant for RedHill Biopharma regarding novel H. pylori therapies and for BioGaia regarding use of probiotics for H. pylori infections.

    • Provenance and peer review Not commissioned; internally peer reviewed.

    Linked Articles